IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

List of Oncology Medication For

Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, including the brain and spinal cord. The goal of treatment is to manage symptoms, slow the progression of the disease, and improve the patient’s quality of life. Treatment options may include:, Medications, Physical therapy, Occupational therapy, Speech therapy, Assistive devices, Lifestyle modificationsh.

Indian Pharma Network

M: +9891296838 / 9811747774
E: med@indianpharmanetwork.co.in

ocrelizumab injection

ocrelizumab injection
for intravenous use Initial U.S. Approval: 2017

Facts about ocrelizumab injection

Approval Date: 2017
Proprietary Name: On Request
Active Ingredient(s): ocrelizumab
Dosage Forms And Strengths: Injection: 300 mg/10 mL (30 mg/mL) in a single-dose vial.
Company: Roche
Diseases: multiple sclerosis
Medicine Approved By: –
European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “ocrelizumab injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

ublituximab-xiiy injection

ublituximab-xiiy injection,
For intravenous use Initial U.S. Approval: 2022

As specified in the prescribing information, ublituximab-xiiy injection is indicated for the treatment of Multiple Sclerosis disease. As per highlights Of prescribing information ublituximab-xiiy injection is CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults .

Facts about ublituximab-xiiy injection

Disease Indications: Multiple Sclerosis
Dosage Forms And Strengths: Injection: 150 mg/6 mL (25 mg/mL) in a single-dose via.
Manufacturer: TG Therapeutics
Usage: Intravenous
Medicine Approved By: Food and Drug Administration (FDA)
Briumvi (ublituximab-xiiy) was approved by the FDA in December 2022

Extra Information:

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “ublituximab-xiiy injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query Form For Medications

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398